ZIM
SGMO

Zacks Investment Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Zacks Investment Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-128,230
Closed -$45.9K – 765
2024
Q2 		$45.9K Sell
128,230
-579,938
-82% -$313K ﹤0.01% 598
2024
Q1 		$475K Buy
708,168
+157,564
+29% +$114K 0.01% 475
2023
Q4 		$299K Buy
+550,604
New +$254K ﹤0.01% 527

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $103B AUM 28.65% 1-Year Est. Return

Zacks Investment Management's SGMO Position: Q3 2024 in Review

Zacks Investment Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2024, closing a stake of 128,230 shares — an estimated $45.9K sold.

Zacks Investment Management first reported a position in SGMO in Q4 2023 and held it in 3 quarters. The position peaked at $475K in Q1 2024. 103 funds tracked by Wall St. Rank hold SGMO as of Q3 2024.

  • Zacks Investment Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2024 after selling out during the quarter.
  • Zacks Investment Management sold 128,230 SANGAMO THERAPEUTICS INC shares in Q3 2024, an estimated $45.9K.
  • Zacks Investment Management first reported a position in SANGAMO THERAPEUTICS INC in Q4 2023 and held it in 3 quarters.
  • Zacks Investment Management's SANGAMO THERAPEUTICS INC position peaked at $475K in Q1 2024.
  • 103 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2024.

Based on Zacks Investment Management's 13F filing for Q3 2024, filed 14 Nov 2024.